Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Free Report) was the target of a large drop in short interest in July. As of July 15th, there was short interest totalling 8,800 shares, a drop of 24.8% from the June 30th total of 11,700 shares. Based on an average daily volume of 6,200 shares, the short-interest ratio is currently 1.4 days. Approximately 1.4% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, StockNews.com assumed coverage on shares of Titan Pharmaceuticals in a research note on Sunday. They set a “sell” rating for the company.
Get Our Latest Stock Analysis on TTNP
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Why Call Options Volume for These 2 Stocks Spiked Together
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- MarketBeat Week in Review – 7/22 – 7/26
- Investing in Commodities: What Are They? How to Invest in Them
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.